Report #2878965

Received Dec 22, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: Nov 10, 2025
Onset: Nov 10, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	2	A5DD7	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Engerix-B late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 45-year-old male patient who received HBV (Engerix B) (batch number A5DD7) for prophylaxis. Previously administered products included Engerix B (received 1st dose on 02-JUL-2025). On 10-NOV-2025, the patient received the 2nd dose of Engerix B. On 10-NOV-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Engerix-B late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 16-DEC-2025 The patient received late 2nd dose.